Cellectis and Servier Expand Collaboration on UCART19 Products

Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A

February 18, 2020 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), and Servier, an international pharmaceutical company, today announced the execution of a binding term sheet to enter into an amendment to the agreement initially signed between the two companies in 2014.

Under the term sheet, Cellectis shall grant to Servier, through an amendment to the agreement, an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including rights to ALLO-501A, an anti-CD19 candidate in which the rituximab recognition domains have been removed, either directly or through its US sublicensee Allogene Therapeutics.

In this amendment, financial terms will be improved to include an additional USD 27.6 million (EUR 25 million) upfront payment, as well as up to USD 410 million (EUR 370 million) in clinical and commercial milestones. The royalty rate will be increased from tiered high single-digit royalties to flat low double-digit royalties based on net sales of products.

In addition, pursuant to the amendment, Cellectis shall regain exclusive control over the five undisclosed allogeneic CAR T-cell targets previously covered by the initial agreement.

The amendment will be effective upon its execution.

“This amendment to our license agreement with Servier provides to Cellectis an attractive economic upside to product candidates targeting CD19 and enriches our proprietary portfolio of targets,” said Dr. André Choulika, Chairman and CEO, Cellectis. “We are committed to positioning Servier and Allogene for streamlined success, so the CD19-directed products have the potential to reach patients faster, while also providing Cellectis the means to expand our proprietary product pipeline.”

About UCART19/ALLO-501 and ALLO-501A

UCART19/ALLO-501 and ALLO-501A are two anti-CD19 allogeneic CAR-T product candidates being jointly developed under a clinical development collaboration between Servier and Allogene Therapeutics based on an exclusive license granted by Cellectis to Servier.

Such products utilize Cellectis’ technologies, including TALEN^® gene editing technology pioneered and controlled by Cellectis. Servier grants to Allogene exclusive rights to UCART19 in the US while Servier retains exclusive rights for all other countries.